A systematic review of pharmacoeconomic evaluations of erlotinib in the first-line treatment of advanced non-small cell lung cancer

Nguyen, Cuc; Petrelli, Fabio; Scuri, Stefania; Nguyen, Binh Thanh; Grappasonni, Iolanda

doi:10.1007/s10198-019-01040-7

Cited by 11 publications

(6 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[29][30][31] Cisplatin, which inhibits DNA replication and damages cell membrane structures, is currently the most common chemotherapeutic agent used for the treatment of advanced NSCLC. [32][33][34] However, the sensitivity of NSCLC to cisplatin decreases with the disease progression, and the emergence of cisplatin resistance will eventually result in chemotherapy failure. 35 Understanding of cisplatin resistance is a prerequisite for the management of chemotherapy resistance in NSCLC.…”

Section: Discussionmentioning

confidence: 99%

<p>LncRNA LINC01116 Contributes to Cisplatin Resistance in Lung Adenocarcinoma</p>

Wang¹,

Gao²,

Chen³

et al. 2020

OTT

View full text Add to dashboard Cite

Background: Long non-coding RNAs (lncRNAs) have been found to contribute to cisplatin resistance in several cancers; however, the role of lncRNA LINC01116 in cisplatin resistance remains unknown in non-small-cell lung cancer. This study aimed to examine the contribution of LINC01116 to cisplatin resistance in lung adenocarcinoma (LAD). Materials and Methods: Cisplatin-resistant A549/DDP cells were generated by treatment with cisplatin by dose escalation. LINC01116 expression was compared between A549 and A549/DDP cells, and between cisplatin-resistant and non-resistant LAD specimens. The cell viability, colony formation, proliferation, migration and invasion were measured using MTT and Transwell assays, and cell apoptosis and cell cycle were detected using flow cytometry. The expression of E-cadherin and Vimentin was quantified. LAD xenografts were modeled in nude mice to investigate the role of LINC01116 on the resistance of LAD to cisplatin. Results: MTT assay measured the IC 50 values of 13.49 ± 1.62 and 3.52 ± 1.33 μg/mL for A549/DDP and A549 cells, respectively. LINC01116 was overexpressed in cisplatin-resistant LAD specimens and A549/DDP cells (P < 0.05). Knockdown of LINC01116 inhibited cell viability, proliferation, migration and invasion, promoted apoptosis and enhanced the sensitivity to cisplatin in A549/DDP cells, while LINC01116 overexpression promoted cell viability, proliferation, migration and invasion, inhibited apoptosis and reduced the sensitivity to cisplatin in A549 cells. LINC01116 knockdown resulted in a 2.1-fold increase in E-cadherin expression and a 56% reduction in Vimentin expression in A549/DDP cells, and LINC01116 overexpression resulted in a 45% reduction in E-cadherin expression and a 1.82fold increase in Vimentin expression in A549 cells. Conclusion: Dysregulation of lncRNA LINC01116 expression results in resistance of LAD to cisplatin via the EMT process. Our findings support the oncogenic role of LINC01116 to promote the development of cisplatin resistance in LAD, and LINC01116 may be a novel predictor of poor response to cisplatin.

show abstract

Section: Discussionmentioning

confidence: 99%

<p>LncRNA LINC01116 Contributes to Cisplatin Resistance in Lung Adenocarcinoma</p>

Wang¹,

Gao²,

Chen³

et al. 2020

OTT

View full text Add to dashboard Cite

show abstract

“…van der Linden et al reported total mean drug costs of €4970 for stage IV patients with first-line chemotherapy or targeted therapy, including costs for day care [22]. Considering that they studied patients irrespective (10) 147 (12) of treatment (thus also including patients receiving supportive care only), and assuming that 55% of diagnosed patients receive supportive care only [12,23], this resembles total mean costs for first-line systemic treatment of €11,044, which is quite similar to our finding of mean drug costs of €12,209 for first-line systemic treatment. In contrast, our results differ substantially from the costs found by Keusters et al [24].…”

Section: Discussionmentioning

confidence: 99%

“…Overall mean costs per year of diagnosis were calculated by dividing the total costs from patients with that same year of diagnosis by the total number of patients in that same year of diagnosis who started systemic treatment. Subsequently, overall mean Although traditional single intervention cost-effectiveness studies based on clinical trial data are widely available [9,10], observational data about the actual costs and OS outcomes associated with systemic treatment regimens for NSCLC in realworld are still scarce. Recently published research on treatment costs for stage IV NSCLC in real-world practice showed that these costs were substantial, despite the fact that the median OS benefit was poor [11]; however, follow-up time was limited and results over the years were lacking.…”

Section: Statisticsmentioning

confidence: 99%

Trends in Drug Costs and Overall Survival in Patients with Metastatic Non-small Cell Lung Cancer in The Netherlands Diagnosed from 2008 Through 2014

Welle

Peters

Deenen

et al. 2020

PharmacoEconomics Open

View full text Add to dashboard Cite

Background The Value-Based Health Care concept defines patient value as patient-relevant outcomes divided by costs. The aim of the present study was to assess the development of systemic treatment costs over the years compared with changes in overall survival (OS) at the level of a diagnosis of stage IV non-small cell lung cancer (NSCLC). Methods All patients diagnosed (in 2008-2014) with stage IV NSCLC and treated with systemic treatment in six Dutch large teaching hospitals (Santeon network) were included. We collected data on OS and amounts of drug units (milligrams) for every drug in the applied systemic cancer treatments, until death. These amounts were multiplied by Dutch unit costs (Euros/mg) expressed in 2018 Euros to construct total drug costs per line of treatment per patient. Costs for day care visits were added for drugs requiring parenteral administration. Results Data were collected from 1214 patients. Median OS and mean total drug costs showed no significant variation over the years (p = 0.437 and p = 0.693, respectively). Mean total drug costs per 1 year of survival ranged from €20,665 to €26,438 during the period under study. Costs for first-line systemic treatment were significantly higher in 2011-2014 compared with 2008-2010. Conclusion This study shows that overall drug costs were stable over the years, despite a relative increase in first-line treatment costs. Median OS remained at around 8 months from year to year. These trend data are very relevant as background for the assessment of costs and achieved outcomes in the more recent years.

show abstract

“…In clinical practice, only a few patients with NSCLC are diagnosed early ( 4 ). Around 70% of patients with NSCLC are not diagnosed until local advancement or metastasis occurs when the lesions become unresectable, resulting in poor long-term prognosis ( 5 , 6 ). Historically, chemotherapy has remained the major treatment for patients with NSCLC who exhibit local advancement or metastasis ( 7 ).…”

Section: Introductionmentioning

confidence: 99%

Comparing the cost-effectiveness of sintilimab + pemetrexed plus platinum and pemetrexed plus platinum alone as a first-line therapy for Chinese patients with nonsquamous non-small cell lung cancer

Shi¹,

Di²,

Li³

et al. 2023

Transl Cancer Res

View full text Add to dashboard Cite

Background: Pemetrexed plus platinum alone is the conventional first-line therapy for locally advanced metastatic nonsquamous non-small cell lung cancer (NSCLC) without targetable genetic aberrations. The ORIENT-11 trial revealed that sintilimab + pemetrexed plus platinum could yield more survival benefits for patients with nonsquamous NSCLC. The present study aimed to assess the cost-effectiveness of sintilimab + pemetrexed plus platinum vs. that of pemetrexed plus platinum alone as the first-line therapy for patients with nonsquamous NSCLC to inform clinically rational drug use and provide a basis for medical decisionmaking.Methods: A partitioned survival model was created to evaluate the cost-effectiveness of two groups from the perspective of the healthcare system in China. The clinical data for adverse event probabilities and extrapolating long-term survival originally collected in a phase III clinical trial (ORIENT-11) were retrieved.Local public databases and literature were used to acquire data on utility and cost. The heemod package in R software was used to calculate the life years (LYs), quality-adjusted LYs (QALYs), and total costs in each group to generate the incremental cost-effectiveness ratio (ICER) in the base case and to conduct deterministic sensitivity analysis (DSA) and probabilistic sensitivity analysis (PSA).Results: Our base case analysis (BCA) revealed that sintilimab combined with pemetrexed plus platinum provided an increase of 0.86 in QALYs with an increasing cost of United State dollar (USD) $4,317.84 relative to pemetrexed plus platinum in Chinese patients with nonsquamous NSCLC who were negative for targetable genetic variations, which induced an ICER of USD $5,020.74/QALY. The ICER value was lower than the set threshold value. The results exhibited strong robustness in the sensitivity analysis. In DSA, the parameter for the overall survival (OS) curve in chemotherapy and the cost of best supportive care were the main factors that impacted the result of the ICER. The PSA indicated that sintilimab and chemotherapy combination therapy was cost-effective.Conclusions: This study suggests that the combination of sintilimab + pemetrexed plus platinum is cost-effective as a first-line therapy in Chinese patients with nonsquamous NSCLC who are negative for targetable genetic variations from the perspective of the healthcare system.

show abstract

A systematic review of pharmacoeconomic evaluations of erlotinib in the first-line treatment of advanced non-small cell lung cancer

Cited by 11 publications

References 46 publications

<p>LncRNA LINC01116 Contributes to Cisplatin Resistance in Lung Adenocarcinoma</p>

<p>LncRNA LINC01116 Contributes to Cisplatin Resistance in Lung Adenocarcinoma</p>

Trends in Drug Costs and Overall Survival in Patients with Metastatic Non-small Cell Lung Cancer in The Netherlands Diagnosed from 2008 Through 2014

Comparing the cost-effectiveness of sintilimab + pemetrexed plus platinum and pemetrexed plus platinum alone as a first-line therapy for Chinese patients with nonsquamous non-small cell lung cancer

Contact Info

Product

Resources

About